Mirati Therapeutics Inc expected to post a loss of $3.55 a share - Earnings Preview

Mirati Therapeutics

24/02/2023 19:32

* Mirati Therapeutics Inc  MRTX.OQ   MRTX.O  is expected
to show a
rise in quarterly revenue when it reports  results on February
28. 
    * The San Diego California-based  company is expected to
report  a
659.9% increase in revenue to $2.272 million from $299 thousand
a year ago, according to the mean estimate from 14 analysts,
based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Mirati Therapeutics
Inc
is for a loss of $3.55 per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 11 "strong buy" or "buy," 8
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Mirati
Therapeutics Inc is $64.5​, above​ its last closing price
of $45.97. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Sep. 30 2022  -3.48       -3.48      -3.09     Beat    11.1
 Jun. 30 2022  -3.47       -3.49      -3.18     Beat    8.8
 Mar. 31 2022  -3.51       -3.49      -3.40     Beat    2.5​
 Dec. 31 2021  -2.90       -3.00      -3.72     Missed  -23.8
 ​​Sep.        -3.03       -2.89      -1.55     Beat    46.3
 30 2021                                                
 Jun. 30 2021  -2.39       -2.40      -3.23     Missed  -34.5​
 Mar. 31 2021  -2.11       -2.13      -2.67     Missed  -25.1
 Dec. 31 2020  -2.20       -2.23      -2.08     Beat    6.9
 This summary was machine generated February 24 at 19:31 GMT. 
All figures in US dollars  unless otherwise stated